AERS Overhaul Will Be Overseen By FDA’s New Bioinformatics Board
Executive Summary
FDA's initiative to develop an advanced Adverse Event Reporting System that has the ability to analyze data and assist medical reviewers in their efforts to spot safety signals will be overseen by a new Bioinformatics Board
You may also be interested in...
FDA IT Infrastructure Inadequate For Managing Foreign Inspections, GAO Says
FDA's ability to oversee drug importation is encumbered by an inaccurate and dysfunctional information technology infrastructure, the Government Accountability Office asserts
FDA IT Infrastructure Inadequate For Managing Foreign Inspections, GAO Says
FDA's ability to oversee drug importation is encumbered by an inaccurate and dysfunctional information technology infrastructure, the Government Accountability Office asserts
Gottlieb’s New Year’s Wish List: Risk Management Plans Out, Science In
The growing use of risk management plans to mitigate risk in the post-marketing setting presents "potential harm to patients and the practice of medicine," FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb said during a speech on drug safety at the Manhattan Institute in New York Nov. 13